Table of Content

1. Executive Summary
 1.1. Global Market Outlook
 1.2. Demand Side Trends
 1.3. Supply Side Trends
 1.4. Analysis and Recommendations
2. Market Overview
 2.1. Market Coverage / Taxonomy
 2.2. Market Definition / Scope / Limitations
3. Key Market Trends
 3.1. Key Trends Impacting the Market
 3.2. Product Innovation / Development Trends
4. Market Background
 4.1. Macro-Economic Factors
  4.1.1. Rise in Expenditure
  4.1.2. Increased Per Capita Expenditure
 4.2. Forecast Factors - Relevance & Impact
  4.2.1. Products in Pipeline
  4.2.2. Regulatory Scenario
  4.2.3. Mergers and Acquisitions
  4.2.4. Collaborative Agreements
  4.2.5. Value Chain
 4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunity Analysis
5. Market Context
 5.1. Adoption and Usage Analysis
 5.2. Market Evolution
 5.3. Product Vs Drug Class Matrix
 5.4. Regulatory Scenario
 5.5. Parent Market Analysis
 5.6. Key Promotional Strategies by Market Players
6. Global Market - Pricing Analysis
 6.1. Regional Pricing Analysis By Therapeutic Area
 6.2. Pricing Break-up
  6.2.1. Manufacturer Level Pricing
  6.2.2. Distributor Level Pricing
 6.3. Global Average Pricing Analysis Benchmark
7. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034
 7.1. Historical Market Value (US$ Mn) Analysis, 2018 to 2023
 7.2. Current and Future Market Value (US$ Mn) Projections, 2024 to 2034
  7.2.1. Y-o-Y Growth Trend Analysis
  7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
 8.1. Introduction / Key Findings
 8.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2018 to 2023
 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2024 to 2034
  8.3.1. Hematology
  8.3.2. Genetic Diseases
  8.3.3. Neurological Diseases
  8.3.4. Oncology
  8.3.5. Infectious Diseases
  8.3.6. Inflammatory Diseases
  8.3.7. Metabolic Diseases
  8.3.8. Pulmonary Diseases
  8.3.9. Kidney Diseases
  8.3.10. Musculoskeletal Diseases
  8.3.11. Endocrine Diseases
  8.3.12. Topical Diseases
 8.4. Market Attractiveness Analysis By Therapeutic Area
9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Drug Type
 9.1. Introduction / Key Findings Drug Type Size, 2018 to 2023
 9.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2024 to 2034
  9.2.1. Originator Drugs
  9.2.2. Generic Drugs
 9.3. Market Attractiveness Analysis By Drug Type
10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Drug Class
 10.1. Introduction / Key Findings Drug Class Size, 2018 to 2023
 10.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2024 to 2034
  10.2.1. Biologics
  10.2.2. Organic Compounds
 10.3. Market Attractiveness Analysis By Drug Class
11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Mode of Administration
 11.1. Introduction / Key Findings Size, 2018 to 2023
 11.2. Current and Future Market Size (US$ Mn) Analysis and Forecast By Mode of Administration, 2024 to 2034
  11.2.1. Injectables
  11.2.2. Oral
 11.3. Market Attractiveness Analysis By Mode of Administration
12. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Distribution Channel
 12.1. Introduction / Key Findings
 12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2018 to 2023
 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024 to 2034
  12.3.1. Hospital Pharmacies
  12.3.2. Specialty Treatment Pharmacies
  12.3.3. Retail Pharmacies
 12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region
 13.1. Introduction
 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2018 to 2023
 13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024 to 2034
  13.3.1. North America
  13.3.2. Latin America
  13.3.3. Europe
  13.3.4. East Asia
  13.3.5. South Asia
  13.3.6. Oceania
  13.3.7. Middle East and Africa (MEA)
 13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
 14.1. Introduction
 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023
 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034
  14.3.1. By Country
   14.3.1.1. United States
   14.3.1.2. Canada
  14.3.2. By Therapeutic Area
  14.3.3. By Drug Type
  14.3.4. By Drug Class
  14.3.5. By Mode of Administration
  14.3.6. By Distribution Channel
 14.4. Market Attractiveness Analysis
 14.5. Market Trends
 14.6. Key Market Participants - Intensity Mapping
 14.7. Drivers and Restraints - Impact Analysis
15. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
 15.1. Introduction
 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023
 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034
  15.3.1. By Country
   15.3.1.1. Germany
   15.3.1.2. Italy
   15.3.1.3. France
   15.3.1.4. United Kingdom
   15.3.1.5. Spain
   15.3.1.6. Rest of Europe
  15.3.2. By Therapeutic Area
  15.3.3. By Drug Type
  15.3.4. By Drug Class
  15.3.5. By Mode of Administration
  15.3.6. By Distribution Channel
 15.4. Market Attractiveness Analysis
 15.5. Market Trends
 15.6. Key Market Participants - Intensity Mapping
 15.7. Drivers and Restraints - Impact Analysis
16. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
 16.1. Introduction
 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023
 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034
  16.3.1. By Country
   16.3.1.1. GCC Countries
   16.3.1.2. South Africa
   16.3.1.3. Rest of Middle East and Africa
  16.3.2. By Therapeutic Area
  16.3.3. By Drug Type
  16.3.4. By Drug Class
  16.3.5. By Mode of Administration
  16.3.6. By Distribution Channel
 16.4. Market Attractiveness Analysis
 16.5. Market Trends
 16.6. Key Market Participants - Intensity Mapping
 16.7. Drivers and Restraints - Impact Analysis
17. Rest of the World Market Analysis 2018 to 2023 and Forecast 2024 to 2034
 17.1. Introduction
 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023
 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034
  17.3.1. By Therapeutic Area
  17.3.2. By Drug Type
  17.3.3. By Drug Class
  17.3.4. By Mode of Administration
  17.3.5. By Distribution Channel
 17.4. Market Attractiveness Analysis
 17.5. Market Trends
 17.6. Key Market Participants - Intensity Mapping
 17.7. Drivers and Restraints - Impact Analysis
18. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034
 18.1. Introduction
  18.1.1. Market Value Proportion Analysis, By Key Countries
  18.1.2. Global Vs. Country Growth Comparison
 18.2. United States Market Analysis
  18.2.1. By Therapeutic Area
  18.2.2. By Drug Type
  18.2.3. By Drug Class
  18.2.4. By Mode of Administration
  18.2.5. By Distribution Channel
 18.3. Canada Market Analysis
  18.3.1. By Therapeutic Area
  18.3.2. By Drug Type
  18.3.3. By Drug Class
  18.3.4. By Mode of Administration
  18.3.5. By Distribution Channel
 18.4. United Kingdom Market Analysis
  18.4.1. By Therapeutic Area
  18.4.2. By Drug Type
  18.4.3. By Drug Class
  18.4.4. By Mode of Administration
  18.4.5. By Distribution Channel
 18.5. Germany Market Analysis
  18.5.1. By Therapeutic Area
  18.5.2. By Drug Type
  18.5.3. By Drug Class
  18.5.4. By Mode of Administration
  18.5.5. By Distribution Channel
 18.6. France Market Analysis
  18.6.1. By Therapeutic Area
  18.6.2. By Drug Type
  18.6.3. By Drug Class
  18.6.4. By Mode of Administration
  18.6.5. By Distribution Channel
 18.7. Italy Market Analysis
  18.7.1. By Therapeutic Area
  18.7.2. By Drug Type
  18.7.3. By Drug Class
  18.7.4. By Mode of Administration
  18.7.5. By Distribution Channel
 18.8. Spain Market Analysis
  18.8.1. By Therapeutic Area
  18.8.2. By Drug Type
  18.8.3. By Drug Class
  18.8.4. By Mode of Administration
  18.8.5. By Distribution Channel
  18.8.6. By Distribution Channel
 18.9. GCC Countries Market Analysis
  18.9.1. By Therapeutic Area
  18.9.2. By Drug Type
  18.9.3. By Drug Class
  18.9.4. By Mode of Administration
  18.9.5. By Distribution Channel
 18.10. South Africa Market Analysis
  18.10.1. By Therapeutic Area
  18.10.2. By Drug Type
  18.10.3. By Drug Class
  18.10.4. By Mode of Administration
  18.10.5. By Distribution Channel
19. Market Structure Analysis
 19.1. Market Analysis by Tier of Companies
 19.2. Market Concentration
 19.3. Market Share Analysis of Top Players
 19.4. Market Presence Analysis
  19.4.1. By Regional footprint of Players
  19.4.2. Product foot print by Players
  19.4.3. Channel Foot Print by Players
20. Competition Analysis
 20.1. Competition Dashboard
 20.2. Competition Benchmarking
 20.3. Competition Deep Dive
  20.3.1. Novartis AG
   20.3.1.1. Overview
   20.3.1.2. Product Portfolio
   20.3.1.3. Analyst Commentary
   20.3.1.4. Key Financials
   20.3.1.5. Recent Developments
   20.3.1.6. Sales Footprint
   20.3.1.7. Strategy Overview
    20.3.1.7.1. Marketing Strategy
    20.3.1.7.2. Product Strategy
    20.3.1.7.3. Channel Strategy
  20.3.2. AbbVie
   20.3.2.1. Overview
   20.3.2.2. Product Portfolio
   20.3.2.3. Analyst Commentary
   20.3.2.4. Key Financials
   20.3.2.5. Recent Developments
   20.3.2.6. Sales Footprint
   20.3.2.7. Strategy Overview
    20.3.2.7.1. Marketing Strategy
    20.3.2.7.2. Product Strategy
    20.3.2.7.3. Channel Strategy
  20.3.3. Bristol Myers Squibb
   20.3.3.1. Overview
   20.3.3.2. Product Portfolio
   20.3.3.3. Analyst Commentary
   20.3.3.4. Key Financials
   20.3.3.5. Recent Developments
   20.3.3.6. Sales Footprint
   20.3.3.7. Strategy Overview
    20.3.3.7.1. Marketing Strategy
    20.3.3.7.2. Product Strategy
    20.3.3.7.3. Channel Strategy
  20.3.4. BioMarin
   20.3.4.1. Overview
   20.3.4.2. Product Portfolio
   20.3.4.3. Analyst Commentary
   20.3.4.4. Key Financials
   20.3.4.5. Recent Developments
   20.3.4.6. Sales Footprint
   20.3.4.7. Strategy Overview
    20.3.4.7.1. Marketing Strategy
    20.3.4.7.2. Product Strategy
    20.3.4.7.3. Channel Strategy
  20.3.5. Amgen Inc.
   20.3.5.1. Overview
   20.3.5.2. Product Portfolio
   20.3.5.3. Analyst Commentary
   20.3.5.4. Key Financials
   20.3.5.5. Recent Developments
   20.3.5.6. Sales Footprint
   20.3.5.7. Strategy Overview
    20.3.5.7.1. Marketing Strategy
    20.3.5.7.2. Product Strategy
    20.3.5.7.3. Channel Strategy
  20.3.6. PTC Therapeutics
   20.3.6.1. Overview
   20.3.6.2. Product Portfolio
   20.3.6.3. Analyst Commentary
   20.3.6.4. Key Financials
   20.3.6.5. Recent Developments
   20.3.6.6. Sales Footprint
   20.3.6.7. Strategy Overview
    20.3.6.7.1. Marketing Strategy
    20.3.6.7.2. Product Strategy
    20.3.6.7.3. Channel Strategy
  20.3.7. AstraZeneca
   20.3.7.1. Overview
   20.3.7.2. Product Portfolio
   20.3.7.3. Analyst Commentary
   20.3.7.4. Key Financials
   20.3.7.5. Recent Developments
   20.3.7.6. Sales Footprint
   20.3.7.7. Strategy Overview
    20.3.7.7.1. Marketing Strategy
    20.3.7.7.2. Product Strategy
    20.3.7.7.3. Channel Strategy
  20.3.8. GlaxoSmithKline Plc
   20.3.8.1. Overview
   20.3.8.2. Product Portfolio
   20.3.8.3. Analyst Commentary
   20.3.8.4. Key Financials
   20.3.8.5. Recent Developments
   20.3.8.6. Sales Footprint
   20.3.8.7. Strategy Overview
    20.3.8.7.1. Marketing Strategy
    20.3.8.7.2. Product Strategy
    20.3.8.7.3. Channel Strategy
  20.3.9. Amgen Inc.
   20.3.9.1. Overview
   20.3.9.2. Product Portfolio
   20.3.9.3. Analyst Commentary
   20.3.9.4. Key Financials
   20.3.9.5. Recent Developments
   20.3.9.6. Sales Footprint
   20.3.9.7. Strategy Overview
    20.3.9.7.1. Marketing Strategy
    20.3.9.7.2. Product Strategy
    20.3.9.7.3. Channel Strategy
  20.3.10. Pfizer Inc.
   20.3.10.1. Overview
   20.3.10.2. Product Portfolio
   20.3.10.3. Analyst Commentary
   20.3.10.4. Key Financials
   20.3.10.5. Recent Developments
   20.3.10.6. Sales Footprint
   20.3.10.7. Strategy Overview
    20.3.10.7.1. Marketing Strategy
    20.3.10.7.2. Product Strategy
    20.3.10.7.3. Channel Strategy
  20.3.11. Johnson & Johnson
   20.3.11.1. Overview
   20.3.11.2. Product Portfolio
   20.3.11.3. Analyst Commentary
   20.3.11.4. Key Financials
   20.3.11.5. Recent Developments
   20.3.11.6. Sales Footprint
   20.3.11.7. Strategy Overview
    20.3.11.7.1. Marketing Strategy
    20.3.11.7.2. Product Strategy
    20.3.11.7.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology



List of Figures

Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034

Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034

Figure 03: Global Market Share Analysis (%), By Therapeutic Area, 2024 & 2034

Figure 04: Global Market Y-o-Y Analysis (%), By Therapeutic Area, 2024 to 2034

Figure 05: Global Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034

Figure 06: Global Market Share Analysis (%), By Drug Type, 2024 & 2034

Figure 07: Global Market Y-o-Y Analysis (%), By Drug Type, 2024 to 2034

Figure 08: Global Market Attractiveness Analysis By Drug Type, 2024 to 2034

Figure 09: Global Market Share Analysis (%), By Drug Class, 2024 & 2034

Figure 10: Global Market Y-o-Y Analysis (%), By Drug Class, 2024 to 2034

Figure 11: Global Market Attractiveness Analysis By Drug Class, 2024 to 2034

Figure 12: Global Market Share Analysis (%), By Mode of Administration, 2024 & 2034

Figure 13: Global Market Y-o-Y Analysis (%), By Mode of Administration, 2024 to 2034

Figure 14: Global Market Attractiveness Analysis By Mode of Administration, 2024 to 2034

Figure 15: Global Market Share Analysis (%), By Distribution Channel, 2024 & 2034

Figure 16: Global Market Y-o-Y Analysis (%), By Distribution Channel , 2024 to 2034

Figure 17: Global Market Attractiveness Analysis, By Distribution Channel, 2024 to 2034

Figure 18: Global Market Share Analysis (%), By Mode of Administration Age Group, 2024 & 2034

Figure 19: Global Market Y-o-Y Analysis (%), By Mode of Administration Age Group, 2024 to 2034

Figure 20: Global Market Attractiveness Analysis By Mode of Administration Age Group, 2024 to 2034

Figure 21: Global Market Share Analysis (%), By Region, 2024 & 2034

Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034

Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034

Figure 24: North America Market Value Share, By Therapeutic Area, 2024 (E)

Figure 25: North America Market Value Share, By Drug Classs 2024 (E)

Figure 26: North America Market Value Share, By Drug Type, 2024 (E)

Figure 27: North America Market Value Share, By Mode of Administration, 2024 (E)

Figure 28: North America Market Value Share, By Distribution Channel, 2024 (E)

Figure 29: North America Market Value Share, By Country, 2024 (E)

Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034

Figure 31: North America Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034

Figure 32: North America Market Attractiveness Analysis By Drug Class, 2024 to 2034

Figure 33: North America Market Attractiveness Analysis By Drug Type, 2024 to 2034

Figure 34: North America Market Attractiveness Analysis By Mode of Administration, 2024 to 2034

Figure 35: North America Market Attractiveness Analysis By Distribution Channel, 2024 to 2034

Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034

Figure 37: Europe Market Value Share, By Therapeutic Area, 2024 (E)

Figure 38: Europe Market Value Share, By Drug Classs 2024 (E)

Figure 39: Europe Market Value Share, By Drug Type, 2024 (E)

Figure 40: Europe Market Value Share, By Mode of Administration, 2024 (E)

Figure 41: Europe Market Value Share, By Distribution Channel, 2024 (E)

Figure 42: Europe Market Value Share, By Country, 2024 (E)

Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034

Figure 44: Europe Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034

Figure 45: Europe Market Attractiveness Analysis By Drug Class, 2024 to 2034

Figure 46: Europe Market Attractiveness Analysis By Drug Type, 2024 to 2034

Figure 47: Europe Market Attractiveness Analysis By Mode of Administration, 2024 to 2034

Figure 48: Europe Market Attractiveness Analysis By Drug Type, 2024 to 2034

Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034

Figure 50: Middle East and Africa Market Value Share, By Therapeutic Area, 2024 (E)

Figure 51: Middle East and Africa Market Value Share, By Drug Class, 2024 (E)

Figure 52: Middle East and Africa Market Value Share, By Drug Type, 2024 (E)

Figure 53: Middle East and Africa Market Value Share, By Mode of Administration, 2024 (E)

Figure 54: Middle East and Africa Market Value Share, By Distribution Channel, 2024 (E)

Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)

Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034

Figure 57: Middle East and Africa Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034

Figure 58: Middle East and Africa Market Attractiveness Analysis By Drug Class, 2024 to 2034

Figure 59: Middle East and Africa Market Attractiveness Analysis By Drug Type, 2024 to 2034

Figure 60: Middle East and Africa Market Attractiveness Analysis By Mode of Administration, 2024 to 2034

Figure 61: Middle East and Africa Market Attractiveness Analysis By Distribution Channel, 2024 to 2034

Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034

Figure 63: Rest of the World Market Value Share, By Therapeutic Area, 2024 (E)

Figure 64: Rest of the World Market Value Share, By Drug Classs 2024 (E)

Figure 65: Rest of the World Market Value Share, By Drug Type, 2024 (E)

Figure 66: Rest of the World Market Value Share, By Mode of Administration, 2024 (E)

Figure 67: Rest of the World Market Value Share, By Distribution Channel, 2024 (E)

Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034

Figure 69: Rest of the World Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034

Figure 70: Rest of the World Market Attractiveness Analysis By Drug Class, 2024 to 2034

Figure 71: Rest of the World Market Attractiveness Analysis By Drug Type, 2024 to 2034

Figure 72: Rest of the World Market Attractiveness Analysis By Mode of Administration, 2024 to 2034

Figure 73: Rest of the World Market Attractiveness Analysis By Distribution Channel, 2024 to 2034

Figure 74: United States Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 75: United States Market Value Share, By Drug Class, 2024 & 2034

Figure 76: United States Market Value Share, By Drug Type, 2024 & 2034

Figure 77: United States Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 78: United States Market Value Share, By Distribution Channel, 2024 & 2034

Figure 79: United States Market Value Analysis (US$ Mn), 2024 & 2034

Figure 80: Canada Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 81: Canada Market Value Share, By Drug Class, 2024 & 2034

Figure 82: Canada Market Value Share, By Drug Type, 2024 & 2034

Figure 83: Canada Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 84: Canada Market Value Share, By Distribution Channel, 2024 & 2034

Figure 85: Canada Market Value Analysis (US$ Mn), 2024 & 2034

Figure 86: United Kingdom Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 87: United Kingdom Market Value Share, By Drug Class, 2024 & 2034

Figure 88: United Kingdom Market Value Share, By Drug Type, 2024 & 2034

Figure 89: United Kingdom Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 90: United Kingdom Market Value Share, By Distribution Channel, 2024 & 2034

Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 & 2034

Figure 92: Germany Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 93: Germany Market Value Share, By Drug Class, 2024 & 2034

Figure 94: Germany Market Value Share, By Drug Type, 2024 & 2034

Figure 95: Germany Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 96: Germany Market Value Share, By Distribution Channel, 2024 & 2034

Figure 97: Germany Market Value Analysis (US$ Mn), 2024 & 2034

Figure 98: France Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 99: France Market Value Share, By Drug Class, 2024 & 2034

Figure 100: France Market Value Share, By Drug Type, 2024 & 2034

Figure 101: France. Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 102: France Market Value Share, By Distribution Channel, 2024 & 2034

Figure 103: France Market Value Analysis (US$ Mn), 2024 & 2034

Figure 104: Italy Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 105: Italy Market Value Share, By Drug Class, 2024 & 2034

Figure 106: Italy Market Value Share, By Drug Type, 2024 & 2034

Figure 107: Italy Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 108: Italy Market Value Share, By Distribution Channel, 2024 & 2034

Figure 109: Italy Market Value Analysis (US$ Mn), 2024 & 2034

Figure 110: Spain Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 111: Spain Market Value Share, By Drug Class, 2024 & 2034

Figure 112: Spain Market Value Share, By Drug Type, 2024 & 2034

Figure 113: Spain Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 114: Spain Market Value Share, By Distribution Channel, 2024 & 2034

Figure 115: Spain Market Value Analysis (US$ Mn), 2024 & 2034

Figure 116: GCC Countries. Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 117: GCC Countries Market Value Share, By Drug Class, 2024 & 2034

Figure 118: GCC Countries Market Value Share, By Drug Type, 2024 & 2034

Figure 119: GCC Countries Market Value Share, By Mode of Administration, 2024 & 2034

Figure 120: GCC Countries Market Value Share, By Distribution Channel, 2024 & 2034

Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 & 2034

Figure 122: South Africa Market Value Share, By Therapeutic Area, 2024 & 2034

Figure 123: South Africa Market Value Share, By Drug Class, 2024 & 2034

Figure 124: South Africa Market Value Share, By Drug Type, 2024 & 2034

Figure 125: South Africa Market Value Share, By Mode of Administration Age Group, 2024 & 2034

Figure 126: South Africa Market Value Share, By Distribution Channel, 2024 & 2034

Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 & 2034

List of Tables

Table 01: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area

Table 02: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type

Table 03: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class

Table 04: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration

Table 05: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel

Table 06: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration Age Group

Table 07: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region

Table 08: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country

Table 09: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area

Table 10: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class

Table 11: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type

Table 12: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration

Table 13: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel

Table 14: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country

Table 15: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area

Table 16: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class

Table 17: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type

Table 18: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration

Table 19: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel

Table 20: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country

Table 21: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area

Table 22: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class

Table 23: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type

Table 24: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration

Table 25: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel

Table 26: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area

Table 27: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class

Table 28: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type

Table 29: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration

Table 30: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel